What does a pharmaceutical buyer actually acquire when it buys a company built with computational drug discovery? A platform story may attract attention. An asset with a specific development path is what the buyer has to underwrite.
On April 27, 2026, Lilly announced an agreement to acquire Ajax Therapeutics. The stated consideration was up to $2.3 billion, including an upfront payment and contingent clinical and regulatory milestones. Ajax’s lead program, AJ1-11095, was in Phase 1 at announcement. The buyer was taking on substantial development uncertainty.[1]
Schrödinger was a founding collaboration partner behind Ajax’s computational discovery work. It was Ajax that was acquired, not Schrödinger. Lilly’s subsequent financial release confirms completion in the second quarter of 2026.[2]
Our reading: the useful lesson is how a capability becomes an asset, and how that asset acquires strategic relevance to a particular buyer. Those are distinct steps, with different capital needs and different owners of risk.
One detail changes the interpretation: Lilly described itself as a founding strategic investor in Ajax. This was a relationship that predated the acquisition announcement.[1] For an executive evaluating financing or a partnership, that raises a more useful question than “What is our AI premium?”
Which evidence should you build next—and which relationship should exist before you need a transaction?
- Lilly / Ajax acquisition announcement · April 27, 2026. Terms, clinical stage at announcement, founding investor relationship.
- Lilly Q2 2026 results · August 5, 2026. Completed acquisition.
- Schrödinger Q2 2026 Form 10-Q · Filed August 5, 2026. Equity proceeds and collaboration milestone.
当一家制药公司收购一家用计算药物发现方法建立起来的公司时，它真正买到的是什么？平台故事可以吸引关注，但买方真正要承担风险、为之定价的，是一个有明确开发路径的资产。
2026 年 4 月 27 日，礼来宣布达成协议收购 Ajax Therapeutics，公布的交易对价为最高 23 亿美元，包括首付款以及取决于临床和监管进展的里程碑付款。宣布时，Ajax 的核心项目 AJ1-11095 处于 I 期临床，买方承担了相当大的研发不确定性。[1]
Schrödinger 是 Ajax 计算药物发现工作背后的创始合作方。但被收购的是 Ajax，而不是 Schrödinger。礼来随后发布的财报确认，交易已于 2026 年第二季度完成。[2]
我们的解读：真正有价值的启示，在于“能力”如何变成“资产”，以及这个资产如何对某个特定买方产生战略意义。这是两个不同的步骤，需要的资本不同，承担风险的人也不同。
有一个细节改变了整件事的解读：礼来称自己是 Ajax 的创始战略投资方。这层关系早在收购宣布之前就已存在。[1]对于正在评估融资或合作的企业高管来说，这引出一个比“我们的 AI 溢价是多少？”更有用的问题：
下一步应该积累哪些证据？哪些关系，应该在你需要交易之前就建立起来？
- Lilly / Ajax acquisition announcement · April 27, 2026. Terms, clinical stage at announcement, founding investor relationship.
- Lilly Q2 2026 results · August 5, 2026. Completed acquisition.
- Schrödinger Q2 2026 Form 10-Q · Filed August 5, 2026. Equity proceeds and collaboration milestone.